SAN DIEGO, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Gyre Therapeutics ( "Gyre" ) ( Nasdaq: GYRE ) , an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present ...

SAN DIEGO, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Gyre Therapeutics ( "Gyre" ) GYRE, an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present at the H.C.

HC Wainwright initiates Gyre with a Buy rating and $18 price target. Hydronidone is projected to reach $6 billion in annual U.S. sales by 2033. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc.

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Tuesday. Shares of MAC Copper Limited MTAL rose sharply during Tuesday's session after the company announced Harmony Gold will acquire them for $1.03 billion. MAC Copper shares jumped 19.9% to $12.17 on Tuesday.